| NENs | neuroendocrine neoplasms |
| GEP-NETs | gastroenteropancreatic neuroendocrine tumors |
| IARC-WHO | International Agency for Research on Cancer—World Health Organization |
| NECs | neuroendocrine cancers |
| MiNEN | mixed neuroendocrine-nonneuroendocrine neoplasms |
| MEN | multiple endocrine neoplasia |
| SINET | small intestine |
| PanNET | pancreatic neuroendocrine tumor |
| RECIST | response evaluation criteria in solid tumors |
| CT | computed tomography |
| US | ultrasonography |
| MRI | magnetic resonance imaging |
| PRRT | peptide receptor radionuclide therapy |
| PPQ | Predictor quotient |
| CI | confidence interval |
| ISH | in situ hybridization |
| CTC | circulating tumor cells |
| EpNET | extrapancreatic neuroendocrine tumor |
| ER | endoscopic resection |
| HR | hazard ratio |
| LAR | long-acting release |
| mOS | median overall survival |
| mPFS | median progression-free survival |
| ORS | objective response rate |
| PET | positron emitting radionuclide |
| PFS | progression-free survival |
| RR | response rate |
| SPECT | gamma emitting radionuclide |
| SSA | somatostatin analogs |
| SSTR | somatostatin receptor |